Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?

J Clin Oncol. 2010 Dec 1;28(34):e719-20; author reply e721-2. doi: 10.1200/JCO.2010.30.4394. Epub 2010 Aug 23.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Biopsy
  • Fluorodeoxyglucose F18*
  • Humans
  • Immunotherapy
  • Lymphoma, Large B-Cell, Diffuse / diagnostic imaging*
  • Lymphoma, Large B-Cell, Diffuse / therapy
  • Positron-Emission Tomography / methods
  • Positron-Emission Tomography / standards*
  • Radiopharmaceuticals*

Substances

  • Antineoplastic Agents
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18